Αποτελέσματα Αναζήτησης
2 Ιουλ 2024 · Describe key unknown and postulated modulators and mediators of vasculopathic and fibrotic processes contributing to common scleroderma complications in the lungs and systemic vasculature.
5 ημέρες πριν · Describe the clinical characteristics of scleroderma patients that place them at high risk of developing PAH. Devise strategies to optimize screening and early detection of PAH in scleroderma patients. Develop best management practices to improve the care of patients with scleroderma-related PAH.
6 Ιουλ 2024 · Epidemiology. Symptomatic joints are present in ~40% (range 12-65%) of patients when diagnosed and overall are present in ~60% (range 24-97%) of patients at sometime during their illness course 6,8.
8 Ιουλ 2024 · There is significant scientific evidence suggesting that systemic scleroderma with diffuse cutaneous involvement (dcSSc) presents a major risk for the development of sclerodermic renal crisis and interstitial lung disease.
15 Ιουλ 2024 · In this Review, the author outlines the complex immunology of systemic lupus erythematosus and how to treat it. Understanding the pathogenesis and clinical manifestations of systemic lupus ...
12 Ιουλ 2024 · Plain radiograph. Plain film features are non-specific. While chest radiographs can be even normal in patients with very early disease, in advanced disease, it may show decreased lung volumes and basal fine to coarse reticulation.
15 Ιουλ 2024 · Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc. ssSSc differs from limited (lcSSc) and diffuse cutaneous (dcSSc) forms by the lack of skin fibrosis.
